BRIEF published on 06/18/2024 at 10:05, 2 years 3 months ago SphingoTec présente PenKid au cours AKI & CRRT à Vicence SphingoTec Biomarqueur AKI Fonction Rénale StyloKid
BRIEF published on 06/18/2024 at 10:05, 2 years 3 months ago SphingoTec Introduces PenKid at AKI & CRRT Course in Vicenza SphingoTec Biomarker AKI Kidney Function PenKid
PRESS RELEASE published on 06/18/2024 at 10:00, 2 years 3 months ago Advancing Kidney Care With Solidified Evidence – SphingoTec Presents PenKid at AKI & CRRT Course in Vicenza SphingoTec introduces kidney function biomarker PenKid at AKI & CRRT Course. PenKid addresses AKI diagnostic gaps with real-time assessment and risk prediction capabilities SphingoTec PenKid Kidney Function Biomarker AKI & CRRT Course Biomarker Integration
BRIEF published on 03/26/2024 at 13:05, 2 years 6 months ago SphingoTec annonce des changements majeurs dans sa direction Biomarqueurs Innovations Diagnostiques Changements De Gestion SphingoTec Soin Critique
BRIEF published on 03/26/2024 at 13:05, 2 years 6 months ago SphingoTec Announces Major Management Changes Biomarkers Management Changes Diagnostic Innovations SphingoTec Critical Care
PRESS RELEASE published on 03/26/2024 at 13:00, 2 years 6 months ago SphingoTec Announces Management Changes SphingoTec announces changes in management team with new appointments. Deborah Bergmann appointed as CEO. Dr. Florian Uhle as CMO and Nicole Witzmann as CFO. Company aims to enhance critical care diagnostics Management Team Biomarkers SphingoTec Deborah Bergmann Critical Care Diagnostics
PRESS RELEASE published on 10/05/2023 at 10:00, 2 years 11 months ago New Formula Leverages Proenkephalin A 119-159 (penKid) for Improved GFR Estimation in Steady-State and Critically Ill Patients
PRESS RELEASE published on 09/06/2023 at 10:00, 3 years ago International Experts Highlight Demand for Diagnostic Innovations as PenKid's Research and Real-World Data Fuels Quest for Improved RRT Liberation Tools
PRESS RELEASE published on 08/31/2023 at 12:30, 3 years ago Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid
PRESS RELEASE published on 05/09/2023 at 10:00, 3 years 4 months ago SphingoTec's Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate
Published on 09/30/2026 at 15:50, 4 hours 26 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 5 hours 39 minutes ago NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 5 hours 45 minutes ago First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week
Published on 09/30/2026 at 14:07, 6 hours 9 minutes ago Worksport COR Energy System Now Available Through Amazon
Published on 09/30/2026 at 13:30, 6 hours 46 minutes ago Nextech3D.ai Engages MZ Group to Lead Strategic Investor Relations Program
Published on 09/30/2026 at 19:45, 31 minutes ago PATRIMOINE ET COMMERCE: MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2026
Published on 09/30/2026 at 18:39, 1 hour 36 minutes ago Advanced Blockchain AG Publishes 2026 Half-Year Report and Advances ABAG 2.0 Strategy
Published on 09/30/2026 at 18:26, 1 hour 49 minutes ago Kaufman & Broad SA: RESULTATS DES NEUF PREMIERS MOIS DE 2026
Published on 09/30/2026 at 18:26, 1 hour 49 minutes ago Kaufman & Broad SA: RESULTS FOR THE FIRST NINE MONTHS OF 2026
Published on 09/30/2026 at 18:44, 1 hour 31 minutes ago Broadcast of the 5th edition of “On the way up”
Published on 09/30/2026 at 18:44, 1 hour 31 minutes ago Diffusion de la 5e édition de “On the way up”
Published on 09/30/2026 at 18:18, 1 hour 57 minutes ago Nombre total de droits de vote et d'actions composant le capital social
Published on 09/30/2026 at 18:15, 2 hours 1 minute ago The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:15, 2 hours 1 minute ago L’État belge et le groupe ENGIE ont convenu de reporter au 4 novembre 2026 la date cible pour la conclusion des Heads of Terms
